Illimis Therapeutics
Fusion protein platform for neurodegenerative and immune diseases
About Illimis Therapeutics
Illimis Therapeutics is a South Korean biotechnology company founded in 2021 by President & CEO Sanghoon Park and scientific co-founders Wonsuk Chung and Chanhyuk Kim. The Seoul-based company specializes in developing therapies for central nervous system (CNS) and immune-related diseases.
The firm's business model is centered on its proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform. This technology is designed to leverage the therapeutic potential of TAM (Tyro3, Axl, Mer) receptor biology, a key pathway in regulating inflammation and immune responses. The GAIA platform is a bispecific fusion protein that aims to clear misfolded proteins, such as amyloid-β, by using the TAM receptor, thereby inducing phagocytosis (the ingestion of bacteria or other material) without causing harmful neuroinflammation, a common side effect of existing antibody drugs. The company's lead drug candidate, ILM01, is being developed for Alzheimer's Disease and is expected to enter preclinical trials in the second half of 2025. Illimis is also developing therapeutics for other neurodegenerative diseases, including ILM02 for tauopathies and ILM03 for synucleinopathies.
Illimis Therapeutics generates revenue through research grants, strategic partnerships, and venture capital funding. The company has secured significant funding, including a $42 million Series B round in July 2025, bringing its total funding to over $60 million. This round included participation from investors like DSC Investment, Woori Venture Partners, Korea Development Bank, and LB Investment. The firm actively pursues collaborations with global pharmaceutical companies and was selected for the '2025 Global Joint Research to Defeat Dementia' program, securing government research funding. In October 2024, Illimis entered into a research collaboration with Eli Lilly and Company to advance its platform for neurodegenerative disease applications. The company is guided by a Scientific Advisory Board that includes Dr. Greg Lemke of the Salk Institute and Dr. Morgan Sheng of the Broad Institute.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jul 2025 | $49M | $195M | Maple Investmet Partners · QUAD Ventures · A Ventures · DSC Investment | ↗ |
| SERIES AOther financing | Apr 2023 | $17M | $67M | Aju IB Investment · Company K Partners · LSK Investment · GS Ventures | ↗ |
Growth signals
Latest recorded traffic for Illimis Therapeutics is 7.1K monthly website visits, up 914.3% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Illimis Therapeutics in the Seoul ecosystem
The Illimis Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A22 investors entered at this stage
Aju IB Investment
Company K Partners- LILSK Investment
GS Ventures- QMQuad Asset Management
WONIK Investment Partners
Industrial Bank of Korea
NH Investment & Securities
STIC Ventures- DPDaily Partners
Woori Venture Partners
DSC Investment
Maple Investmet Partners
QUAD Ventures
A Ventures
LB Investment
Korea Development Bank
Hana Ventures
Schmidt
TS investment
Shinhan Venture Investment
S&S Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Illimis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Illimis Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








